Monoclonal antibodies “for use in SubB2M immunoassays”, a vague description and in typical style of this management. Is it not the big advantage of SuB2M (and the licensed IP) that it is a specific ligand that can detect the Neu5Gc better than antibodies against Neu5Gc? If that is so, what are the antibodies directed against? Against the SubB2M? If so, does this mean that the CA125/SubB2M ELIZA does not work as promisingly as announced on 17 August 2021?
Monoclonal antibodies “for use in SubB2M immunoassays”, a vague...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
-0.015(2.68%) |
Mkt cap ! $60.37M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 59.0¢ | 54.5¢ | $124.5K | 222.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15062 | 54.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.0¢ | 16027 | 1 |
View Market Depth
| Last trade - 15.57pm 05/09/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |